國立高雄大學圖資館 |

Ethics and clinical neuroinnovationfundamentals, stakeholders, case studies, and emerging issues /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Ethics and clinical neuroinnovationedited by Laura Weiss Roberts.
Reminder of title:	fundamentals, stakeholders, case studies, and emerging issues /
other author:	Roberts, Laura Weiss.
Published:	Cham :Springer International Publishing :2023.
Description:	xii, 353 p. :ill. (some col.), digital ;24 cm.
Contained By:	Springer Nature eBook
Subject:	BrainDiseases
Online resource:	https://doi.org/10.1007/978-3-031-14339-7
ISBN:	9783031143397$q(electronic bk.)

Ethics and clinical neuroinnovationfundamentals, stakeholders, case studies, and emerging issues /
Ethics and clinical neuroinnovationfundamentals, stakeholders, case studies, and emerging issues /[electronic resource] :edited by Laura Weiss Roberts. - Cham :Springer International Publishing :2023. - xii, 353 p. :ill. (some col.), digital ;24 cm.

Section 1: Fundamentals: the imperative for novel clinical therapeutics for mental disorders -- Chapter 1: The case for neuroinnovation: Health burdens associated with psychiatric, addiction-related, and co-occurring disorders -- Chapter 02: Neuroinnovation in medicine: History and future -- Chapter 03: Clinical neuroinnovation: Ethical frameworks and emerging issues -- Chapter 04: Changing contexts of neuroinnovation: Societal considerations -- Chapter 05: Changing contexts of neuroinnovation: Societal considerations -- Chapter 06: The NIH's BRAIN2025 agenda: Attention to related ethical considerations -- Section 2: Special Topics in Clinical Neuroinnovation -- Chapter 07: In the surgical suite: Neurosurgery and neuroinnovation, and the ethics of neurostimulation for severe obesity -- Chapter 08: In the midst of uncertainty: Neuroinnovation at the edge of consciousness -- Chapter 09: On the edges: The ethics of human studies with psychedelic substances -- Chapter 10: In the courts: Emerging neuroscience technologies used for forensic purposes: ethical and legal implications -- Chapter 11: Into the wild: A comment on neuroethics startups - Moving from lab to society -- Section 3: Neuroethics and Innovation: Inquiry informed by the Roberts Valence Model -- Chapter 12: Introduction to our project: Understanding ethically-salient perspectives of diverse societal stakeholders in innovative neuroscience research on mental disorders -- Chapter 13: Qualitative phase: Codebook development -- Chapter 14: Qualitative findings: Diverse stakeholder perspectives on ethical considerations in innovative neuroscience research involving human volunteers -- Chapter 15: Qualitative findings: A focus on professional stakeholder perspectives on the environments and challenges of innovative neuroscience research -- Chapter 16: Qualitative findings: A focus on professional stakeholder perspectives on additional issues in research and clinical innovation in the brain -- Chapter 17: Pilot quantitative phase: Amazon MTurk as a novel approach to stakeholder-based neuroethics survey research.

New ways of understanding the brain - its nature, its capacities, its function, and its dysfunction - hold great promise for human wellbeing. Novel therapeutics spurred by this understanding have important roles addressing many clinical conditions, including Alzheimer Disease, depression, addiction, and obsessive-compulsive disorder. This unique title explores a wide range of groundbreaking sciences and clinical practices for brain-based conditions, including deep brain stimulation, optogenetics, technology-delivered therapies, predictive testing, and new clinical uses of ketamine, cannabis, and other psychoactive substances. An introduction to the imperative to develop new treatments for devastating brain disorders and the state of current therapeutics in psychiatry, addiction, and behavioral disorders is presented, and chapters from leading physician-scientists and neuroethicists outline the clinical and the ethical issues arising in innovation and in the creation of new therapeutics for brain diseases. Written by renowned thought leaders in their fields, the book presents tightly written contributions on novel qualitative and quantitative data from stakeholders in the field, including neuroscientist-clinicians, people living with mental illness and/or addictions, and oversight/policy stakeholders. Concise, anticipatory, and centered on the principles governing human biomedical research and innovation in developing novel therapeutics for brain disorders, Ethics and Clinical Neuroinnovation will be of great value to clinicians, researchers, and students from a vast array of backgrounds, including neuroethics, neuroscience, psychology, psychiatry, philosophy, entrepreneurship, and the law.

ISBN: 9783031143397$q(electronic bk.)

Standard No.: 10.1007/978-3-031-14339-7doiSubjects--Topical Terms:

945749
Brain
--Diseases

LC Class. No.: RC386.2

Dewey Class. No.: 174.29689

Ethics and clinical neuroinnovationfundamentals, stakeholders, case studies, and emerging issues /
LDR:04872nmm a2200325 a 4500 001 639474
003 DE-He213
005 20230201034637.0
006 m d
007 cr nn 008maaau
008 231025s2023 sz s 0 eng d
020 $a 9783031143397$q(electronic bk.)
020 $a 9783031143380$q(paper)
024 7 $a 10.1007/978-3-031-14339-7 $2 doi
035 $a 978-3-031-14339-7
040 $a GP $c GP
041 0 $a eng
050 4 $a RC386.2
072 7 $a PSAN $2 bicssc
072 7 $a MED057000 $2 bisacsh
072 7 $a PSAN $2 thema
082 0 4 $a 174.29689 $2 23
090 $a RC386.2 $b .E84 2023
245 0 0 $a Ethics and clinical neuroinnovation $h [electronic resource] : $b fundamentals, stakeholders, case studies, and emerging issues / $c edited by Laura Weiss Roberts.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2023.
300 $a xii, 353 p. : $b ill. (some col.), digital ; $c 24 cm.
505 0 $a Section 1: Fundamentals: the imperative for novel clinical therapeutics for mental disorders -- Chapter 1: The case for neuroinnovation: Health burdens associated with psychiatric, addiction-related, and co-occurring disorders -- Chapter 02: Neuroinnovation in medicine: History and future -- Chapter 03: Clinical neuroinnovation: Ethical frameworks and emerging issues -- Chapter 04: Changing contexts of neuroinnovation: Societal considerations -- Chapter 05: Changing contexts of neuroinnovation: Societal considerations -- Chapter 06: The NIH's BRAIN2025 agenda: Attention to related ethical considerations -- Section 2: Special Topics in Clinical Neuroinnovation -- Chapter 07: In the surgical suite: Neurosurgery and neuroinnovation, and the ethics of neurostimulation for severe obesity -- Chapter 08: In the midst of uncertainty: Neuroinnovation at the edge of consciousness -- Chapter 09: On the edges: The ethics of human studies with psychedelic substances -- Chapter 10: In the courts: Emerging neuroscience technologies used for forensic purposes: ethical and legal implications -- Chapter 11: Into the wild: A comment on neuroethics startups - Moving from lab to society -- Section 3: Neuroethics and Innovation: Inquiry informed by the Roberts Valence Model -- Chapter 12: Introduction to our project: Understanding ethically-salient perspectives of diverse societal stakeholders in innovative neuroscience research on mental disorders -- Chapter 13: Qualitative phase: Codebook development -- Chapter 14: Qualitative findings: Diverse stakeholder perspectives on ethical considerations in innovative neuroscience research involving human volunteers -- Chapter 15: Qualitative findings: A focus on professional stakeholder perspectives on the environments and challenges of innovative neuroscience research -- Chapter 16: Qualitative findings: A focus on professional stakeholder perspectives on additional issues in research and clinical innovation in the brain -- Chapter 17: Pilot quantitative phase: Amazon MTurk as a novel approach to stakeholder-based neuroethics survey research.
520 $a New ways of understanding the brain - its nature, its capacities, its function, and its dysfunction - hold great promise for human wellbeing. Novel therapeutics spurred by this understanding have important roles addressing many clinical conditions, including Alzheimer Disease, depression, addiction, and obsessive-compulsive disorder. This unique title explores a wide range of groundbreaking sciences and clinical practices for brain-based conditions, including deep brain stimulation, optogenetics, technology-delivered therapies, predictive testing, and new clinical uses of ketamine, cannabis, and other psychoactive substances. An introduction to the imperative to develop new treatments for devastating brain disorders and the state of current therapeutics in psychiatry, addiction, and behavioral disorders is presented, and chapters from leading physician-scientists and neuroethicists outline the clinical and the ethical issues arising in innovation and in the creation of new therapeutics for brain diseases. Written by renowned thought leaders in their fields, the book presents tightly written contributions on novel qualitative and quantitative data from stakeholders in the field, including neuroscientist-clinicians, people living with mental illness and/or addictions, and oversight/policy stakeholders. Concise, anticipatory, and centered on the principles governing human biomedical research and innovation in developing novel therapeutics for brain disorders, Ethics and Clinical Neuroinnovation will be of great value to clinicians, researchers, and students from a vast array of backgrounds, including neuroethics, neuroscience, psychology, psychiatry, philosophy, entrepreneurship, and the law.
650 0 $a Brain $x Diseases $x Treatment $x Moral and ethical aspects. $3 945749
650 1 4 $a Neuroscience. $3 297547
650 2 4 $a Neuropsychology. $3 188060
650 2 4 $a Neurology. $3 211583
700 1 $a Roberts, Laura Weiss. $3 456501
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-031-14339-7
950 $a Behavioral Science and Psychology (SpringerNature-41168)